James Singleton joins Numab Therapeutics executive management team

Numab Therapeutics, an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland, has named James Singleton (pictured) as its new general counsel. The Boston counsel will also serve on Numab’s Executive Management Team.

Singleton most recently served as general counsel for Waypoint Capital, a global investment manager headquartered in Switzerland focusing on life sciences and asset management, and its affiliate Gurnet Point Capital, a healthcare fund. During his 20 plus years of experience, Singleton has served in a number of high responsibility roles, including, head of legal for Merck Biosimilars, Merck Global Business Development & Merck Ventures. He was also associate general counsel for Healthcare Business of Merck. Earlier in his career, Singleton was part of the legal teams at Acceptys as well as Serono International.